Alzheimer’s biotech eyes $300M in a scaled-up IPO

Axovant Sciences, heading toward Phase III with an ex-GlaxoSmithKline treatment for Alzheimer’s disease, has upped its IPO hopes to more than $300 million, betting it can win FDA approval where many others have failed.

Source: www.fiercebiotech.com

---